NYSE · BMY
Healthcare · Drug Manufacturers - General
$63.73
Down-$0.37 (-0.58%)
Updated Sep 16, 2026, 10:33 AM
SID Score
7.1/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
BMY closed at $63.73 after 20 trading sessions, down 3.51% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $63.94 | $64.13 | $63.15 | $63.73 | 10M |
| Sep 14, 2026 | $64.59 | $65.29 | $63.91 | $64.10 | 6.9M |
| Sep 11, 2026 | $64.15 | $64.20 | $63.27 | $63.64 | 7.06M |
| Sep 10, 2026 | $64.92 | $64.92 | $63.73 | $63.75 | 6.5M |
| Sep 9, 2026 | $64.57 | $65.05 | $64.2608 | $64.41 | 6.57M |
| Sep 8, 2026 | $65.66 | $65.8931 | $64.395 | $64.69 | 9.52M |
| Sep 4, 2026 | $67.24 | $67.72 | $66.575 | $66.82 | 4.83M |
| Sep 3, 2026 | $68.08 | $68.24 | $66.615 | $68.09 | 6.22M |
| Sep 2, 2026 | $66.815 | $67.73 | $66.7501 | $67.66 | 7.83M |
| Sep 1, 2026 | $67.58 | $68.04 | $66.645 | $66.92 | 6.93M |
| Aug 31, 2026 | $66.25 | $67.199 | $65.9102 | $66.81 | 12.68M |
| Aug 28, 2026 | $66.77 | $66.84 | $66.19 | $66.58 | 5.54M |
| Aug 27, 2026 | $66.59 | $67.47 | $66.20 | $66.95 | 4.67M |
| Aug 26, 2026 | $67.735 | $68.00 | $67.32 | $67.57 | 7.51M |
| Aug 25, 2026 | $66.42 | $68.05 | $66.42 | $67.92 | 7.91M |
| Aug 24, 2026 | $67.405 | $67.405 | $66.45 | $67.28 | 6.81M |
| Aug 21, 2026 | $65.79 | $67.55 | $65.13 | $67.01 | 6.84M |
| Aug 20, 2026 | $67.225 | $67.54 | $65.45 | $65.47 | 9.49M |
| Aug 19, 2026 | $66.80 | $68.64 | $66.61 | $67.61 | 13.89M |
| Aug 18, 2026 | $65.30 | $66.38 | $65.00 | $66.05 | 9.41M |
The latest Smart Investors Daily articles mentioning BMY.
BMY research
Company profile and research snapshot.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | HSBC | Hold | — |
| Aug 5, 2026 | Argus Research | Buy | — |
| Aug 3, 2026 | Citigroup | Neutral | — |
| Jul 31, 2026 | Wells Fargo | Equal-Weight | — |
| Jul 31, 2026 | Truist Securities | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 11, 2026
Bristol-Myers Squibb Company (NYSE:BMY) said its experimental CAR-T cell therapy, arlocabtagene autoleucel (arlo-cel), met the main goal of a mid-stage trial in patients with advanced multiple myeloma who had already gone through four major classes of standard treatments. The therapy produced a statistically significant and clinically meaningful improvement in overall response rates. It also met […]
Yahoo · Sep 10, 2026
Bristol Myers Squibb (BMY) reached $63.75 at the closing of the latest trading day, reflecting a -1.02% change compared to its last close.
Yahoo · Sep 10, 2026
Bristol Myers growth brands and pipeline progress are boosting momentum, but generic pressure on its legacy portfolio warrants caution.
Yahoo · Sep 10, 2026
Fresh off a regulatory victory for its groundbreaking cancer drug, Revolution Medicines could capture even more of the oncology market.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BMY.
